ThermoGenesis Holdings to Announce Financial Results for the Fourth Quarter Ended December 31, 2021 and Provide a Corporate Strategic Update
ThermoGenesis Holdings (Nasdaq: THMO) will announce its financial results for Q4 2021 on March 28, 2022, after market close. A conference call will follow at 1:30 p.m. PT. The company specializes in automated cell processing technologies for cell and gene therapy, including the CAR-TXpress™ platform for CAR-T immunotherapy. Webcast access will be available for three months post-call on their investor page.
- Company is a leader in automated cell processing tools for CAR-T and other therapies.
- Upcoming Q4 financial results expected to provide strategic updates.
- None.
Conference Call to be Held on March 28, 2022
RANCHO CORDOVA, Calif., March 23, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the fourth quarter ended December 31, 2021 and provide a corporate strategic update on Monday, March 28, 2022, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET.
To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please visit: https://thermogenesis.com/investors/news-and-events/events-webcasts.
A webcast replay will be available on ThermoGenesis' website for three months by visiting the Investor page of the Company's website at www.thermogenesis.com.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.thermogenesis.com.
Company Contact: Wendy Samford
916-858-5191
ir@ThermoGenesis.com
Investor Contact: Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com
View original content:https://www.prnewswire.com/news-releases/thermogenesis-holdings-to-announce-financial-results-for-the-fourth-quarter-ended-december-31-2021-and-provide-a-corporate-strategic-update-301508660.html
SOURCE ThermoGenesis Holdings, Inc.
FAQ
When will ThermoGenesis Holdings announce its Q4 2021 financial results?
What time is the conference call for ThermoGenesis Holdings?
What is the main product of ThermoGenesis Holdings?
How can I access the ThermoGenesis Holdings conference call?
